Iovance Biotherapeutics reported Q4 2025 revenue of $87 million, beating estimates, while receiving FDA fast-track designation for lifileucel in non-small cell lung cancer and reporting strong sarcoma trial data.
A randomized trial of 210 advanced lung cancer patients found that administering checkpoint inhibitor immunotherapy in the morning nearly doubled progression-free survival and extended overall survival by nearly a year compared to later-day dosing.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06526897 |
Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma |
NOT_YET_RECRUITING | NA |
| NCT06277154 |
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma |
RECRUITING | PHASE2 |
| NCT05961761 |
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients |
RECRUITING | PHASE2 |
| NCT05515068 |
Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas |
NOT_YET_RECRUITING | |
| NCT05182164 |
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas |
RECRUITING | PHASE2 |
| NCT05116800 |
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma |
WITHDRAWN | PHASE2 |
| NCT04906876 |
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas |
WITHDRAWN | PHASE2 |
| NCT04480502 |
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04420975 |
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT04332874 |
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg |
RECRUITING | PHASE2 |
